EYPT | Ticker Profile - Titan Protect

EYPT

EyePoint, Inc.

Healthcare · Biotechnology · NGM

$11.78

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.1B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-4.66

Based on estimated future earnings — lower means cheaper

Rev Growth

+161.7%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-102.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$34.00

+189% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 12 analysts covering this stock

About EyePoint, Inc.

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

https://eyepoint.bio

Country: United States Employees: 214 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.511

Good returns relative to risk taken

Kelly Fraction

0.0398

Modest edge detected — smaller position warranted

Calmar Ratio

0.168

Drawdown risk outweighs the returns — higher risk profile

Annual Return

11.1%

Historical annualised return based on price data

Max Drawdown

-65.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.77

Significantly more volatile than the market

52W High

$19.11

38% below the year high

52W Low

$6.85

72% above the year low

Avg Volume

1,030,122

Average daily shares traded — higher means easier to buy and sell

Short Ratio

16.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

17.8%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-3.51

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

46.82

Heavy leverage — higher financial risk if revenues decline

Current Ratio

6.66

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

5.97

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-450.7%

Profit from core operations before interest and tax

Free Cash Flow

$-168,724,992

Negative — the business is spending more than it generates

Revenue (TTM)

$8M

Total revenue over the last 12 months

Net Income

$-271,599,008

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$68.00

Target Median

$34.00

Target Low

$20.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go